Moderna, Inc.（MRNA）今日盘中股价大涨5.02%，引发市场关注。
消息面上，Moderna宣布已向美国FDA、欧洲EMA、加拿大卫生部及澳大利亚TGA同步提交其mRNA流感疫苗mRNA-1010的上市授权申请。这一关键进展标志着该疫苗在全球主要市场的监管审批正式启动，若获批将成为公司继新冠疫苗后的又一重磅产品，为季节性流感预防提供创新解决方案。
此外，Moderna近期还公布了2025年16亿至20亿美元的营收目标，并强化商业团队建设以推动季节性疫苗业务发展，进一步巩固了投资者对公司长期增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.